World's Best Scientists 2026 revealed!
Constantine S. Tam

Constantine S. Tam

D-Index & Metrics

Medicine

D-Index
76
Citations
28872
World Ranking
18643
National Ranking
625

Overview

Constantine S. Tam is affiliated with the University of Melbourne in Australia and has contributed extensively to medical research, particularly within the field of Medicine. Their work spans several subfields including Genetics, Pathology and Forensic Medicine, Oncology, Hematology, and Immunology.

The scientist's research primarily focuses on chronic lymphocytic leukemia and lymphoma, as well as treatments related to chronic myeloid leukemia and CAR-T cell therapy. Additional areas of study include immunodeficiency and autoimmune disorders, viral-associated cancers and disorders, and advanced breast cancer therapies.

Among the recent papers authored or co-authored by Constantine S. Tam are:

  • Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study, 2021, The Lancet Oncology
  • A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study, 2020, Blood
  • Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study, 2021, The Lancet
  • Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia, 2022, New England Journal of Medicine
  • COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus, 2020, Leukemia

Frequent co-authors involved in their research include:

  • Wojciech Jurczak
  • Paolo Ghia
  • Stephen Opat
  • Alessandra Tedeschi
  • Chan Y. Cheah

Constantine S. Tam's work has been published predominantly in high-impact medical journals, with frequent venues including:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • Blood Advances
  • Hematological Oncology

The scientist's research contributions cover key topics such as:

  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • CAR-T cell therapy research
  • Immunodeficiency and Autoimmune Disorders
  • Viral-associated cancers and disorders
  • Advanced Breast Cancer Therapies

Best Publications

  • Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Stephen J. Schuster;Michael R. Bishop;Constantine S. Tam;Edmund K. Waller

  • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

    J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos

  • Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

    Jan A. Burger;Alessandra Tedeschi;Paul M. Barr;Tadeusz Robak

  • Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

    Constantine S. Tam;Susan O'Brien;William Wierda;Hagop Kantarjian

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

    Philip A. Thompson;Constantine S. Tam;Susan M. O'Brien;William G. Wierda

  • Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

    Stephen J. Schuster;Constantine S. Tam;Peter Borchmann;Nina Worel

  • Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

    Constantine S Tam;Mary Ann Anderson;Christiane Pott;Rishu Agarwal

  • Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

    Talha Munir;Jennifer R. Brown;Susan O'Brien;Jacqueline C. Barrientos

  • Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

    Julie R. McMullen;Esther J. H. Boey;Jenny Y. Y. Ooi;John F. Seymour;John F. Seymour

  • Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

    Piers Blombery;Piers Blombery;Mary Ann Anderson;Mary Ann Anderson;Mary Ann Anderson;Jia-nan Gong;Jia-nan Gong;Rachel Thijssen;Rachel Thijssen

  • Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.

    Susan O'Brien;Susan O'Brien;Jeffrey A Jones;Steven E Coutre;Anthony R Mato;Anthony R Mato

  • Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

    John F Seymour;John F Seymour;Shuo Ma;Danielle M Brander;Michael Y Choi

  • A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.

    Constantine S. Tam;Stephen Opat;Shirley D'Sa;Wojciech Jurczak

  • Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.

    Anthony R Mato;Nirav N Shah;Wojciech Jurczak;Chan Y Cheah

  • The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

    Ian W. Flinn;Peter Hillmen;Marco Montillo;Zsolt Nagy

  • Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions

    Marie Levade;Elodie David;Cédric Garcia;Pierre-Alexandre Laurent

  • Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

    Constantine Si Lun Tam;Judith Trotman;Judith Trotman;Stephen Opat;Jan A Burger

  • Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

    Meletios A. Dimopoulos;Alessandra Tedeschi;Judith Trotman;Ramón García-Sanz

  • The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

    Mary Ann Anderson;Mary Ann Anderson;Mary Ann Anderson;Jing Deng;John F. Seymour;John F. Seymour;Constantine Tam;Constantine Tam

Frequent Co-Authors

John F. Seymour
John F. Seymour Peter MacCallum Cancer Centre
Andrew W. Roberts
Andrew W. Roberts Walter and Eliza Hall Institute of Medical Research
Susan O'Brien
Susan O'Brien University of California, Irvine
David Ritchie
David Ritchie Peter MacCallum Cancer Centre
William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center
Paolo Ghia
Paolo Ghia Vita-Salute San Raffaele University
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Peter Hillmen
Peter Hillmen St James's University Hospital
Jennifer R. Brown
Jennifer R. Brown Harvard University
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online pathways in healthcare offers accessible alternatives for advancing your career, especially for those balancing work or family commitments. For registered nurses wanting to earn a bachelor’s degree without attending in-person practicums, rn to bsn online no clinicals options can be a convenient solution.

Nurses aspiring to the highest levels in their field may consider dnp online programs, which are increasingly available in flexible, accelerated formats. Some programs also cater to those seeking easier options, with online dnp programs without clinicals reducing the hands-on requirements while maintaining academic rigor.

For those wishing to quickly enter the workforce, an lpn fast track program provides streamlined training for aspiring practical nurses. Each of these pathways addresses different needs, offering diverse opportunities for students who want to earn a nursing or healthcare degree online, advance their careers, or transition into new roles in medicine.

Best Scientists Citing Constantine S. Tam

Trending Scientists

Recently Published Articles